Lavoltidine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lavoltidine
Accession Number
DB12884
Type
Small Molecule
Groups
Investigational
Description

Lavoltidine has been used in trials studying the diagnostic of Reflux, Gastroesophageal and Gastroesophageal Reflux Disease.

Structure
Thumb
Synonyms
Not Available
External IDs
AH 23844 / AH-23844
Categories
UNII
X16K5179V5
CAS number
76956-02-0
Weight
Average: 359.474
Monoisotopic: 359.232125194
Chemical Formula
C19H29N5O2
InChI Key
VTLNPNNUIJHJQB-UHFFFAOYSA-N
InChI
InChI=1S/C19H29N5O2/c1-23-19(21-18(15-25)22-23)20-9-6-12-26-17-8-5-7-16(13-17)14-24-10-3-2-4-11-24/h5,7-8,13,25H,2-4,6,9-12,14-15H2,1H3,(H,20,21,22)
IUPAC Name
{1-methyl-5-[(3-{3-[(piperidin-1-yl)methyl]phenoxy}propyl)amino]-1H-1,2,4-triazol-3-yl}methanol
SMILES
CN1N=C(CO)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Lavoltidine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Lavoltidine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Lavoltidine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Lavoltidine.Experimental, Illicit
AmphetamineAmphetamine may decrease the sedative activities of Lavoltidine.Approved, Illicit, Investigational
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Lavoltidine.Approved, Investigational
BenzphetamineBenzphetamine may decrease the sedative activities of Lavoltidine.Approved, Illicit
Benzylpenicilloyl PolylysineLavoltidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Lavoltidine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Lavoltidine.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Lavoltidine.Approved, Investigational
CefpodoximeLavoltidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CefuroximeLavoltidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Lavoltidine.Illicit, Withdrawn
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Lavoltidine.Approved, Investigational
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Lavoltidine.Approved, Investigational
DasatinibLavoltidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DelavirdineLavoltidine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DexmethylphenidateLavoltidine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DextroamphetamineDextroamphetamine may decrease the sedative activities of Lavoltidine.Approved, Illicit
DiethylpropionDiethylpropion may decrease the sedative activities of Lavoltidine.Approved, Illicit
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Lavoltidine.Approved, Investigational
Ferric CarboxymaltoseLavoltidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateLavoltidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Lavoltidine.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Lavoltidine.Approved, Investigational
GepefrineGepefrine may decrease the sedative activities of Lavoltidine.Experimental
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Lavoltidine.Approved, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Lavoltidine.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Lavoltidine.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Lavoltidine.Approved
IronLavoltidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranLavoltidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateLavoltidine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Lavoltidine.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Lavoltidine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Lavoltidine.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Lavoltidine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Lavoltidine.Investigational
MephentermineMephentermine may decrease the sedative activities of Lavoltidine.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Lavoltidine.Approved
MethamphetamineMethamphetamine may decrease the sedative activities of Lavoltidine.Approved, Illicit
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Lavoltidine.Experimental
MethylphenidateLavoltidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MidomafetamineMidomafetamine may decrease the sedative activities of Lavoltidine.Experimental, Illicit, Investigational
MMDAMMDA may decrease the sedative activities of Lavoltidine.Experimental, Illicit
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Lavoltidine.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Lavoltidine.Approved, Investigational
PazopanibLavoltidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhenterminePhentermine may decrease the sedative activities of Lavoltidine.Approved, Illicit
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Lavoltidine.Approved, Investigational, Vet Approved
PseudoephedrinePseudoephedrine may decrease the sedative activities of Lavoltidine.Approved
RisedronateLavoltidine can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
RitobegronRitobegron may decrease the sedative activities of Lavoltidine.Investigational
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Lavoltidine.Approved, Investigational
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Lavoltidine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C11805
PubChem Compound
55473
PubChem Substance
347829039
ChemSpider
50093
ChEBI
6550
ChEMBL
CHEMBL2110857
Wikipedia
Lavoltidine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedDiagnosticGastroesophageal Reflux Disease / Reflux, Gastroesophageal1
2CompletedDiagnosticGastroesophageal Reflux Disease / Reflux, Gastroesophageal1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.291 mg/mLALOGPS
logP2.94ALOGPS
logP2.03ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)13.45ChemAxon
pKa (Strongest Basic)8.74ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.44 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity116.23 m3·mol-1ChemAxon
Polarizability41.31 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Benzylpiperidines
Direct Parent
N-benzylpiperidines
Alternative Parents
Phenylmethylamines / Phenoxy compounds / Phenol ethers / Benzylamines / Secondary alkylarylamines / Aralkylamines / Alkyl aryl ethers / Triazoles / Heteroaromatic compounds / Trialkylamines
show 5 more
Substituents
N-benzylpiperidine / Benzylamine / Phenoxy compound / Phenol ether / Phenylmethylamine / Alkyl aryl ether / Secondary aliphatic/aromatic amine / Aralkylamine / Benzenoid / Monocyclic benzene moiety
show 19 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
piperidines, aromatic ether, primary alcohol, triazoles (CHEBI:6550)

Drug created on October 20, 2016 18:59 / Updated on July 02, 2018 19:42